Phase I clinical trial - Pédiatrie Tumeurs cérébrales

MS100070-0087
Pédiatrie Tumeurs cérébrales
Ouvert depuis le: 05.25.2024
Site: Paris
Public cible
Enfant
Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors.
Description de l'essai
This study consists of 2 parts: Dose Escalation Part 1 and Dose Expansion Part 2. The Dose Escalation Part 1 will evaluate the safety and tolerability of Avelumab in combination with Lenvatinib and determine the recommended Avelumab and Lenvatinib dose for expansion. Dose Expansion Part 2 will assess the efficacy of Avelumab in combination with Lenvatinib by Progression-free Survival in participants with pre-defined primary central nervous system (CNS) tumors.
Vignette
FRANCOIS DOZ
Investigateur principal